PharmaSource Podcast

• ADC Manufacturing Demand Outpaces Capacity in US Market

  “Twenty years ago, who knew that ADCs and next-generation bioconjugates were going to be so exciting, so successful?”Campbell Bunce, Chief Scientific Officer at Abzena, reflects on the strategic positioning that has placed his company at the forefront of one of pharma’s fastest-growing segments.Campbell leads a global team spanning discovery, development, and GMP manufacturing at Abzena, where he has spent nearly a decade building the company’s capabilities in complex modalities. His background as an immunologist, combined with 18 years in biotech before joining Abzena, gives him a unique perspective on translating scientific innovation into commercial manufacturing reality.In this conversation on the PharmaSource podcast, Campbell discusses Abzena’s strategic focus on antibody-drug conjugates (ADCs) and bioconjugates, the company’s approach to proprietary platform development, and how the CDMO is responding to increased demand driven by geopolitical manufacturing shifts and clinical successes in the space.Read more.

  --------  

  26:18

  --------

  26:18
• Breaking the Death Spiral: How to Rescue Failing CDMO Relationships Before It’s Too Late

  “When I walked into the tech transfer, we were a million dollars over budget, six months behind schedule, and struggling to make a single successful batch,” says Amy Gamber.Amy Gamber, Executive Director, Lifecycle Lead at Kyverna Therapeutics, specializes in crisis recovery for late-stage biotech and cell and gene therapy programs. With 20+ years of CMC leadership experience at Atara Biotherapeutics, CSL Seqirus, and Amgen, she’s built a career fixing what others couldn’t.In this PharmaSource podcast interview, Amy shares how to identify warning signs before minor issues become million-dollar problems, strategies for rescuing failing tech transfers, and what it takes to restart a manufacturing facility dormant for two years.Full article

  --------  

  34:37

  --------

  34:37
• Markus Sieger Reflects on 25 Years Building Polpharma into Europe’s Generic Manufacturing Leader

  “We have to be transparent down to the last person in the organization, what the organization is doing, and where the issues are. We have to celebrate wins. We have to talk about the good things people do.”Markus Sieger serves as CEO of Polpharma Group, one of Central and Eastern Europe’s largest pharmaceutical manufacturers. With 25 years at the company, and 10  years as CEO, he has transformed the Polish generic and OTC medicines manufacturer into a regional powerhouse producing 400 million packages annually across Poland, Kazakhstan, and Western European markets. Markus will step down as CEO of Polpharma Group in January 2026, transitioning to the company’s supervisory board.In this conversation, Markus reflects on building Polpharma’s market leadership through culture transformation and digital-first operations, the challenges that shaped his leadership journey, and the evolution of Europe’s generic medicines industry.Read more.

  --------  

  31:31

  --------

  31:31
• CordenPharma CEO on Scaling GLP-1 Production and Competing in Complex Modalities

  “Our goal is to be recognized for exceptional reliability in our services and manufacturing, while helping our customers bring the most innovative medicines to market.” Dr. Michael Quirmbach, CEO and President of CordenPharma, has overseen remarkable growth at the full-service CDMO since joining in 2014. Under his leadership, the company has tripled its workforce to 3,000 employees and increased revenue from €245 million to nearly €1 billion while expanding capabilities across peptides, injectables, and high-potency oncology products. Michael, who holds a PhD in chemistry and began his career as a scientist before transitioning to business leadership, brings 25 years of CDMO experience to his role. In a recent PharmaSource podcast recorded at CPHI, he discussed CordenPharma’s €900 million expansion in peptide manufacturing, the company’s strategy for complex modalities, and how AI is transforming pharmaceutical manufacturing operations.Read more.

  --------  

  14:02

  --------

  14:02
• What BioPlan's 22-Year Data Reveals About the Future of Biopharmaceutical Outsourcing

  "If you can't demonstrate international quality standards, nobody is going to take a chance on a million-dollar batch to save a few dollars on their manufacturing. It just won't happen."Eric Langer is President of BioPlan Associates, where he has systematically documented the evolution of the biomanufacturing industry since the early 2000s. In the latest PharmaSource podcast episode, Eric explains why biopharmaceutical outsourcing budgets are projected to surge 11% in 2025, the cost of talent constraints, and the rise of complex modalities like cell and gene therapies. He shares critical insights from BioPlan's 22nd annual report on what manufacturers must prioritize to succeed in an increasingly competitive landscape.Read more.

  --------  

  34:35

  --------

  34:35

Mais podcasts de Ciência

Podcasts em tendência em Ciência

Sobre PharmaSource Podcast